Key facts
- Aera Therapeutics’s last known valuation is $505.0M (Feb 2023).
- It has raised $187.9M; the latest was Early Stage VC in Sep 2025.
- Notable investors include GV, F-Prime Capital, Lux Capital, ARCH Venture Partners, Altitude Life Science Ventures — 7 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 7 names
- ·Watchlist + deal alerts for Aera Therapeutics
- ·The full record, as it builds
Funding rounds
No funding rounds for Aera Therapeutics are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Aera Therapeutics
Developer of a health technology platform intended to serve transformative genetic medicines. The company's proprietary protein nanoparticle (PNP) genetic medicine delivery platform leverages the discovery of endogenous, human proteins derived from retroelements that can self-assemble to form capsid-like structures and which can package and transfer nucleic acid cargo, combining the benefits of an endogenous, self-assembling system with the engineerability of a protein-based system and has the potential, helping health sector with researching on genetic medicines across modalities and therapeutic areas.
- Sector
- Healthcare
- HQ
- Cambridge, MA, United States
- Founded
- 2021
- Employees
- 85
- Website
- aeratx.com/
- Ownership
- Privately Held (backing)
Aera Therapeutics doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Aera Therapeutics shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Aera Therapeutics in its N-PORT filings yet. We sweep new filings monthly.